EI
VRDN icon

EAM Investors’s Viridian Therapeutics VRDN Stock Holding History

EAM Investors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-78,763
Closed -$2M – 379
2023
Q1 		$2M Sell
78,763
-20,877
-21% -$669K 0.39% 109
2022
Q4 		$2.91M Buy
99,640
+45,934
+86% +$1.06M 0.6% 43
2022
Q3 		$1.1M Buy
+53,706
New +$965K 0.24% 187

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

EAM Investors's VRDN Position: Q2 2023 in Review

EAM Investors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 78,763 shares — an estimated $2M sold.

EAM Investors first reported a position in VRDN in Q3 2022 and held it in 3 quarters. The position peaked at $2.91M in Q4 2022. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • EAM Investors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EAM Investors sold 78,763 Viridian Therapeutics shares in Q2 2023, an estimated $2M.
  • EAM Investors first reported a position in Viridian Therapeutics in Q3 2022 and held it in 3 quarters.
  • EAM Investors's Viridian Therapeutics position peaked at $2.91M in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.